An observational study in Sepsis, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Ain Shams University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Sepsis by Ain Shams University — 8 open to participants now, 10 under way, none of them phase 3. Sepsis · Ain Shams University.
Among the 30 studies in Sepsis by Ain Shams University, this one is the 2nd largest by planned enrollment of the 19 observational ones that give a count, is one of 7 that started in 2024, is one of 19 observational ones, and was the 23rd registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →8 of the 30 studies in Sepsis by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 25–60
Ain Shams University · Sites in Egypt
Ages 18+
Ain Shams University
Ages 18+ · Women only
By country, each count listing its studies:
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is close to the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 72 across the 11 interventional studies, 80 across the 19 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Sepsis by Ain Shams University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07922213Ain Shams UniversityEffect of Rutin and Vitamin C on Outcomes in Adults With Sepsis Admitted to the Intensive Care Unit | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Sepsis by Ain Shams University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim of this study is to predict the prognostic values of Neutrophil/ Lymphocyte ratio and Lactate/Albumin ratio in the outcome of patients with sepsis and septic shock with lower respiratory tract infection, also to compare between them regarding sensitivity and specificity.
Lower respiratory tract infection (LRTI) is one of the most common infectious diseases that lead to admission of patients to ICU. It includes a wide range of respiratory infections; such as pneumonia, bronchitis, empyema and lung abscess. Furthermore, it is associated with considerable morbidity and mortality. Because delay in the ICU admission of patients with LRTI has been shown to be associated with increased mortality, it can be helpful to predict the mortality of LRTI patients in hospitals.
Sepsis is a life-threatening medical emergency induced by uncontrolled systemic inflammatory response of the host to infection. Without an early and aggressive management, sepsis can rapidly lead to organ failure, tissue hypoperfusion, and death. Bacterial infections cause most cases of sepsis, but it can also be a result of other infections; such as viral, fungal or parasitic infections. Sepsis-3 definitions for sepsis management were established in 2016 according to the Surviving Sepsis Campaign guidelines. They define sepsis as "a life-threatening organ dysfunction caused by a dysregulated host response to infection", and septic shock as "a subset of sepsis in which underling circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality".
According to Sepsis-3 criteria, sepsis and septic shock are currently diagnosed as follows: sepsis-suspected or documented infection plus SOFA (Sequential Organ Failure Assessment) score ≥2; septic shock-sepsis plus vasopressor therapy needed to maintain mean arterial pressure (MAP) ≥65 mmHg plus lactate ≥2 mmol/L (18 mg/L) despite adequate fluid resuscitation. However these diagnosis criteria, the early evaluation of sepsis severity and prognosis is still imprecise and significant research is being performed to address this issue.
The neutrophil/lymphocyte ratio (NLR) was studied in order to provide an easier way to diagnose sepsis. This ratio can be calculated both from the absolute number of neutrophils and lymphocytes, and from their relative number. The importance of this report derives from the fact that physiological stress causes an increase in the number of neutrophils and a decrease in the number of lymphocytes. Sepsis stimulates lymphocyte apoptosis, so this ratio is increased in these cases. Septic shock causes a dramatic decrease in lymphocyte count, so the NLR ratio increases significantly.
Increased lactate production is a prognostic marker of generalized hypoxia in distributive shock. Previous studies have reported that lactate levels are a dependable parameter in diagnosis, therapeutic evaluation, and prognosis in circulatory shock. Increased lactate levels are used worldwide for early diagnosis, management, and in risk stratification of patients with septic shock .
Albumin is a negative acute-phase protein, and its levels can reflect the magnitude of inflammation. In critically ill patients, the degree of hypoalbuminemia thus represents the severity of the inflammatory response. Consequently, it may be a prognostic biomarker in patients with sepsis .
Although lactate and albumin values independently predict mortality, the ratio of lactate to albumin (L/A ratio) is superior as a predictor to lactate or albumin alone. This result has been recorded in studies conducted in recent years .
Adults with lower respiratory tract infection confirmed septic patients admitted to Ain Shams University Hospitals ICU
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Data collection: (upon admission to ICU) All the study subjects will be submitted to: I) Careful clinical evaluation including: * Demographics. * Comorbid conditions. * Medication usage (including intravenous fluids and vasoactive medications). * Vital signs . * Mental status (Glasgow Coma Score) * SOFA (Sequential Organ Failure Assessment) score. * Duration of antibiotics treatment. II) Laboratory Investigations including: * Complete blood picture (CBC): including Neutrophils and Lymphocytes count. * Serum albumin and serum lactate. * Prothrombin time and concentrations. * Liver function tests (LFTs), serum creatinine and urea. * Electrolytes, arterial blood gases. * Highly sensitive C -reactive protein (Hs CRP). III) Microbiological investigations: Various body fluid cultures, including sputum, blood, and urine will be obtained to identify source of sepsis. All investigations will be done at Ain Shams University, central lab unit.
Detect the mortality due to sepsis with lower respiratory tract infection
Detect the mortality due to sepsis and septic shock in patients with lower respiratory tract infection in ICU
Time frame: From date of randomization until the date of death during the study period ( 12-18 months)
The prognostic values of Neutrophil/Lymphocyte ratio and Lactate/Albumin ratio in Sepsis
predict the prognostic values of Neutrophil/Lymphocyte ratio and Lactate/Albumin ratio in the outcome of septic patients with lower respiratory tract infection in ICU
Time frame: From date of randomization until the date of discharge from the ICU or death during the study period ( 12-18 months )
The duration of intensive care unit stay
The duration of intensive care unit stay in days from admission to ICU until discharge or death during the period of the study (12-18 months)
Time frame: From date of randomization until the date of discharge from the ICU or death during the study period ( 12-18 months )
The requirement for vasoactive medications
The requirement for vasoactive medications regarding the doses in microgram per kilogram per minute and the duration in days
Time frame: From date of randomization until the date of discharge from the ICU or death during the study period ( 12-18 months )
Mechanical ventilatory support and renal replacement therapy
The need of mechanical ventilatory support and the need of renal replacement therapy and its duration in days
Time frame: From date of randomization until the date of discharge from the ICU or death during the study period ( 12-18 months )
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2025, 12 months after the start.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 12 months is below that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.